The role of gut bacteria in cancer treatment outcomes for kidney cancer patients
Gut Microbiome and Cancer Immunotherapy Outcomes in Advanced Renal Cell Carcinoma
This study is looking at how the bacteria in your gut might influence how well immunotherapy works for people with advanced kidney cancer, aiming to find out which gut bacteria can help predict treatment success and side effects, so doctors can better personalize care for each patient.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-11060888 on NIH RePORTER |
What this research studies
This research investigates how the gut microbiome affects the outcomes of immunotherapy in patients with advanced renal cell carcinoma (RCC). By analyzing gut bacteria profiles before treatment, the study aims to identify specific bacterial species and pathways that correlate with patient responses to immunotherapy, including both positive outcomes and adverse effects. The research will also explore how changes in the gut microbiome during treatment relate to T-cell activation and overall patient survival. This could help tailor immunotherapy approaches to individual patients based on their gut microbiome composition.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with advanced renal cell carcinoma who are eligible for immunotherapy.
Not a fit: Patients with early-stage renal cell carcinoma or those not receiving immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to personalized immunotherapy strategies that improve treatment outcomes and reduce side effects for kidney cancer patients.
How similar studies have performed: Previous research has shown promising results in understanding the gut microbiome's influence on cancer treatment outcomes, suggesting that this approach could yield valuable insights.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Fedirko, Veronika — University of Tx Md Anderson Can Ctr
- Study coordinator: Fedirko, Veronika
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.